Publications
Detailed Information
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ou, Sai-Hong Ignatius | - |
dc.contributor.author | Kwak, Eunice L. | - |
dc.contributor.author | Siwak-Tapp, Christina | - |
dc.contributor.author | Dy, Joni | - |
dc.contributor.author | Bergethon, Kristin | - |
dc.contributor.author | Clark, Jeffrey W. | - |
dc.contributor.author | Camidge, D. Ross | - |
dc.contributor.author | Solomon, Benjamin J. | - |
dc.contributor.author | Maki, Robert G. | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Christensen, James | - |
dc.contributor.author | Tan, Weiwei | - |
dc.contributor.author | Wilner, Keith D. | - |
dc.contributor.author | Salgia, Ravi | - |
dc.contributor.author | Iafrate, A. John | - |
dc.date.accessioned | 2020-04-27T11:35:14Z | - |
dc.date.available | 2020-04-27T11:35:14Z | - |
dc.date.created | 2020-04-08 | - |
dc.date.issued | 2011-05 | - |
dc.identifier.citation | Journal of Thoracic Oncology, Vol.6 No.5, pp.942-946 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.other | 95271 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165514 | - |
dc.description.abstract | Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier Inc. | - |
dc.title | Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1097/JTO.0b013e31821528d3 | - |
dc.citation.journaltitle | Journal of Thoracic Oncology | - |
dc.identifier.wosid | 000289554100015 | - |
dc.identifier.scopusid | 2-s2.0-79955458487 | - |
dc.citation.endpage | 946 | - |
dc.citation.number | 5 | - |
dc.citation.startpage | 942 | - |
dc.citation.volume | 6 | - |
dc.identifier.sci | 000289554100015 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GENE COPY NUMBER | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordPlus | ERLOTINIB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordPlus | LEADS | - |
dc.subject.keywordAuthor | Non-small cell lung cancer | - |
dc.subject.keywordAuthor | De novo MET amplification NSCLC | - |
dc.subject.keywordAuthor | 18(F)-FDG PET/CT | - |
dc.subject.keywordAuthor | Crizotinib (PF02341066) | - |
dc.subject.keywordAuthor | MET polysomy | - |
dc.subject.keywordAuthor | Anaplastic lymphoma kinase (ALK) re-arranged NSCLC | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.